Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 19, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 375,000 ordinary shares of 25 pence each.
- Purchase Date: September 19, 2005.
- Purchase Price: 1,378.72 pence per share.
- Treasury Holdings Post-Purchase: 114,303,000 shares.
- Shares in Issue (excluding Treasury): 5,832,949,803 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 375,000 shares to be held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase (375,000 shares at 1,378.72 pence).
- Confirm the updated total share count excluding treasury shares (5,832,949,803).
- Review the company's broader share buyback program limits and remaining authorization from the May 25, 2005 AGM.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.